Cargando…

A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma

Risk stratification in myeloma requires an accurate assessment of the presence of a range of molecular abnormalities including the differing IGH translocations and the recurrent copy number abnormalities that can impact clinical behavior. Currently, interphase fluorescence in situ hybridization is u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boyle, Eileen M, Proszek, Paula Z, Kaiser, Martin F, Begum, Dil, Dahir, Nasrin, Savola, Suvi, Wardell, Christopher P, Leleu, Xavier, Ross, Fiona M, Chiecchio, Laura, Cook, Gordon, Drayson, Mark T, Owen, Richard G, Ashcroft, John M, Jackson, Graham H, Anthony Child, James, Davies, Faith E, Walker, Brian A, Morgan, Gareth J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310140/ https://www.ncbi.nlm.nih.gov/pubmed/25287954 http://dx.doi.org/10.1002/gcc.22222

Ejemplares similares

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma
por: Walker, Brian A, et al.
Publicado: (2015)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial
por: Boyd, Kevin D, et al.
Publicado: (2011)

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients
por: Shah, V, et al.
Publicado: (2018)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
por: Walker, B A, et al.
Publicado: (2014)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients
por: Jones, John R., et al.
Publicado: (2019)

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2010)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

The evolving role and utility of off-label drug use in multiple myeloma
por: Stoeckle, James H, et al.
Publicado: (2021)

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
por: Morgan, Gareth J, et al.
Publicado: (2011)

Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial
por: Croft, James, et al.
Publicado: (2020)

Differential RNA splicing as a potentially important driver mechanism in multiple myeloma
por: Bauer, Michael A., et al.
Publicado: (2020)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Structural variants shape the genomic landscape and clinical outcome of multiple myeloma
por: Ashby, Cody, et al.
Publicado: (2022)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study
por: Cook, Gordon, et al.
Publicado: (2019)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma
por: Mikulasova, Aneta, et al.
Publicado: (2017)

Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications
por: Huang, He, et al.
Publicado: (2022)

Dissecting racial disparities in multiple myeloma—clues from differential immunoglobulin levels
por: Bunce, C. M., et al.
Publicado: (2020)

Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer
por: Ghamlouch, Hussein, et al.
Publicado: (2021)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Multiple myeloma with cells typically seen in storage diseases
por: Boturão Neto, Edmir, et al.
Publicado: (2011)

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma
por: Johnson, David C., et al.
Publicado: (2016)

Intellectually able adults with autism spectrum disorder show typical resting-state EEG activity
por: Li, Qianliang, et al.
Publicado: (2022)

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

MMSET is the key molecular target in t(4;14) myeloma
por: Mirabella, F, et al.
Publicado: (2013)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
por: Podar, Klaus, et al.
Publicado: (2021)

A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2021)

Recent advances in the treatment of multiple myeloma: a brief review
por: Bobin, Arthur, et al.
Publicado: (2022)

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
por: Jackson, Graham H, et al.
Publicado: (2019)

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
por: Kolovos, Spyros, et al.
Publicado: (2019)

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
por: Jackson, Graham H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ms1skissoopnmch83e4ouo94ag